News

Media

Conferences

Publications

Clinical

Events

Resources

Video

January 11, 2016

The Aftermath of Hepatitis C Drugs on Specialty Spending

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Related Videos

Image Credit: © alenamozhjer - stock.adobe.com

Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com

Image Credit: © Andrey Popov - stock.adobe.com

Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com

Pharmacy technician working in a pharmacy -- Image credit: sofiko14 | stock.adobe.com

Team of pharmacists -- Image credit: Jacob Lund | stock.adobe.com

Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com

World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards

Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com

Image Credit: © Cavan - stock.adobe.com

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.